October 18, 2019
FOR IMMEDIATE RELEASE
ProciseDx and Lumiphore Announce Diagnostic Technology
San Diego, CA / Berkeley, CA, October 8, 2019. ProciseDx and Lumiphore announced that they have signed an agreement on incorporation of Lumiphore’s new metal luminescent reporter technology in ProciseDx™ point-of-care diagnostic tests.
Under the agreement, ProciseDx has the exclusive worldwide rights to use Lumiphore’s new technology in its diagnostic tests. First offerings will be for inflammatory and autoimmune diseases such as celiac and metabolic syndromes.
“Lumiphore can bring the benefits of lanthanide-based homogenous mix-and-read assays, known as time-resolved fluorescence resonance energy transfer (TR-FRET) assays, to the diagnostic markets, from central labs to point-of-care applications. Detection sensitivity and simplicity of use as well as material cost reductions in reagent use, labor, and reader platforms are all benefits of Lumiphore’s new reporter technology,” said Steve Blose, Lumiphore’s Chief Business Officer.
“Using Lumiphore’s technology enables ProciseDx to offer rapid, quantitative and easy point-of-care tests. We are excited to bring these tests to market in 2020.” said Dr. Larry Mimms, ProciseDx’s CEO.
ProciseDx is a diagnostics company committed to the development and commercialization of a broad portfolio of point-of-care diagnostic tests for use in physician offices, retail clinics and urgent care. ProciseDx currently has 24 employees, 10,000 sq. ft. of office, laboratory and manufacturing space and is ISO13485 certified. ProciseDx is headquartered in San Diego, California and is a wholly owned subsidiary of Nestlé Health Science.